3629 results for «684»
3629 results
Redefining precision and performance in TAVI: advancing clinical outcomes with the Evolut FX+ system
10 Oct 2025 – From AICT-AsiaPCR 2025
Delve into advanced transcatheter aortic valve implantation (TAVI) with the Evolut FX plus system, focusing on its application in patients with small annulus and coronary artery disease (CAD). This session details step-by-step deployment, patient selection, imaging analysis, and highlights the distinctions from the previous Evolut R...
Complex femoral access for TAVI in bicuspid aortic stenosis - LIVE Case
30 Sep 2025 – From PCR Gulf Valves 2025
74 year-old male with history of multiple PCI, PAD, Type 2 DM, presented a symptomatic bicuspid aortic stenosis with a preserved LV function.
They implant a myval 26 mm by right femoral artery access with a right radial secondary access, after a predilation (Balloon 20mm). They prepare...
Step-by-step TAVI for mixed bicuspid aortic valve disease - LIVE Case
30 Sep 2025 – From PCR Gulf Valves 2025
A 65-year-old female with a history of diabetes and moderate left ventricular dysfunction (LVEF 50%) presented with symptomatic severe bicuspid aortic stenosis associated with moderate-to-severe aortic regurgitation. A 26 mm Sapien Resilia valve was implanted under local anesthesia via femoral artery access, with right radial secondary...
Management of mitral regurgitation patients undergoing TMVI screening
13 Jan 2022
This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.
TriValve: a propensity score-matched analysis of transcatheter tricuspid valve treatment vs. medical treatment in patients with severe tricuspid regurgitation
28 Sep 2019
At TCT 2019 in San Francisco - USA, Maurizio Taramasso presented the results of the TriValve Registry. Read the summary and analysis by Tom Cahill.
Author
PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial
18 May 2021
Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)
01 Apr 2025
Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.
Author
30 years of primary PCI – a tale of perseverance
16 May 2023
Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.
Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial
05 Mar 2023
Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.
Author
